

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|------|----|--------|---|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | DEC 01 | ChemPort single article sales feature unavailable |
| NEWS | 3 | JAN 06 | The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo |
| NEWS | 4 | JAN 07 | WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data |
| NEWS | 5 | FEB 02 | Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE |
| NEWS | 6 | FEB 02 | GENBANK enhanced with SET PLURALS and SET SPELLING |
| NEWS | 7 | FEB 06 | Patent sequence location (PSL) data added to USGENE |
| NEWS | 8 | FEB 10 | COMPENDEX reloaded and enhanced |
| NEWS | 9 | FEB 11 | WTEXTILES reloaded and enhanced |
| NEWS | 10 | FEB 19 | New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art |
| NEWS | 11 | FEB 19 | Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01 |
| NEWS | 12 | FEB 23 | Several formats for image display and print options discontinued in USPATFULL and USPAT2 |
| NEWS | 13 | FEB 23 | MEDLINE now offers more precise author group fields and 2009 MeSH terms |
| NEWS | 14 | FEB 23 | TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms |
| NEWS | 15 | FEB 23 | Three million new patent records blast AEROSPACE into STN patent clusters |
| NEWS | 16 | FEB 25 | USGENE enhanced with patent family and legal status display data from INPADOCDB |
| NEWS | 17 | MAR 06 | INPADOCDB and INPAFAMDB enhanced with new display formats |
| NEWS | 18 | MAR 11 | EPFULL backfile enhanced with additional full-text applications and grants |
| NEWS | 19 | MAR 11 | ESBIOBASE reloaded and enhanced |
| NEWS | 20 | MAR 20 | CAS databases on STN enhanced with new super role for nanomaterial substances |
| NEWS | 21 | MAR 23 | CA/CAPLUS enhanced with more than 250,000 patent equivalents from China |
| NEWS | 22 | MAR 30 | IMSPATENTS reloaded and enhanced |
| NEWS | 23 | APR 03 | CAS coverage of exemplified prophetic substances enhanced |
| NEWS | 24 | APR 07 | STN is raising the limits on saved answers |

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:19:07 ON 17 APR 2009

| | | |
|----------------------|------------|---------|
| => file reg | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.22 | 0.22 |

FILE 'REGISTRY' ENTERED AT 14:19:30 ON 17 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9
DICTIONARY FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10597283.str



```

chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
1-10 4-7 5-9 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :
```


G1:C,N

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
```

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 14:19:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 67132 TO ITERATE

100.0% PROCESSED 67132 ITERATIONS 606 ANSWERS
SEARCH TIME: 00.00.02

L2 606 SEA SSS FUL L1

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 185.88 | 186.10 |

FILE 'CAPLUS' ENTERED AT 14:19:54 ON 17 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2009 VOL 150 ISS 17
FILE LAST UPDATED: 16 Apr 2009 (20090416/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12 full
L3 86 L2

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|---------------------|------------------|
| FULL ESTIMATED COST | 0.50 | 186.60 |

FILE 'REGISTRY' ENTERED AT 14:20:03 ON 17 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9
DICTIONARY FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10597283a.str



chain nodes :

13 14

ring nodes :

1 2 3 4 5 6 7 8 9 16 17 18 19 20

chain bonds :

1-16 2-14 3-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 16-17 16-20 17-18 18-19 19-20

exact/norm bonds :

1-16 2-14 3-13 4-7 5-9 7-8 8-9 16-17 16-20 17-18 18-19 19-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 16 :

G1:C,N

G2:H,CH3,Et

G3:C,O,S,N

G4:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 13:CLASS
14:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

L4 STR



G1 C,N

G2 H, Me, Et

G3 C,O,S,N

G4 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 14 full

FULL SEARCH INITIATED 14:23:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1005 TO ITERATE

100.0% PROCESSED 1005 ITERATIONS

206 ANSWERS

SEARCH TIME: 00.00.01

L5 206 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

188.76

375.36

FILE 'CAPLUS' ENTERED AT 14:24:00 ON 17 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2009 VOL 150 ISS 17
FILE LAST UPDATED: 16 Apr 2009 (20090416/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15 full

L6 4 L5

=> d ibib abs hitstr tot

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1450617 CAPLUS

DOCUMENT NUMBER: 150:5766

TITLE: Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo[4,5-b]pyridin-1-yl)methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors

INVENTOR(S): Even, Luc; Hoornaert, Christian

PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.

SOURCE: PCT Int. Appl., 27pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:



| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2008145843 | A1 | 20081204 | WO 2008-FR536 | 20080416 |
| W: | AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

| | | | | |
|------------|----|----------|--------------|----------|
| FR 2915198 | A1 | 20081024 | FR 2007-2808 | 20070418 |
|------------|----|----------|--------------|----------|

PRIORITY APPLN. INFO.: FR 2007-2808 A 20070418

OTHER SOURCE(S): MARPAT 150:5766

GI




AB Title compds. I [X = H, halo, alkyl, alkoxy, OH, etc.; A = absent, a bond, O, S, NH and derivs., CONH and derivs., SO₂NH and derivs., alk(en)ylene; R₁, R₂ = independently H, alkyl, CN, halo, etc.; their free bases, acid addition salts, hydrates and solvates] were prepared as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors for treating MGL- and FAAH-related pathologies. Thus, amidation of 4-(3-trifluoromethylphenyl)-1-piperazinecarbonyl chloride with 2-amino-6-chloro-3-nitropyridine, coupling of the chloride with 4-chlorophenylboronic acid, reduction of the nitro intermediate and diazotization/cyclization of the amine gave triazolopyridine carboxamide II. In a radioenzymic test measuring the in vitro inhibitory activity of I towards MGL, II inhibited MGL with IC₅₀ = 0.002 μ M. In a radioenzymic test measuring the in vitro inhibitory activity of I towards FAAH, II inhibited FAAH with IC₅₀ = 0.002 μ M. I are useful for treating and preventing pathologies in which endogenous 2-arachidonoylglycerol and 1(3)-arachidonoylglycerol and/or other substrate metabolized by MLG and/or in which endogenous anandamide and/or other substrate metabolized by FAAH are implied.

IT 1072874-85-1P, [5-(Furan-3-yl)-[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of triazolopyridine carboxamides as selective monoacyl glycerol lipase or mixed monoacyl glycerol lipase and fatty acid amide hydrolase inhibitors)

RN 1072874-85-1 CAPLUS

CN Methanone, [5-(3-furanyl)-3H-1,2,3-triazolo[4,5-b]pyridin-3-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1279746 CAPLUS

DOCUMENT NUMBER: 149:493691

TITLE: Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo[4,5-b]pyridin-1-yl)methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors

INVENTOR(S): Even, Luc; Hoornaert, Christian

PATENT ASSIGNEE(S): Sanofi Aventis, Fr.

SOURCE: Fr. Demande, 22pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| ----- | ---- | ----- | ----- | ----- |
| FR 2915198 | A1 | 20081024 | FR 2007-2808 | 20070418 |
| WO 2008145843 | A1 | 20081204 | WO 2008-FR536 | 20080416 |
| W: | AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRIORITY APPLN. INFO.: FR 2007-2808 A 20070418

OTHER SOURCE(S): MARPAT 149:493691

GI



AB Title compds. I [X = H, halo, alkyl, alkoxy, OH, etc.; A = absent, a bond, O, S, NH and derivs., CONH and derivs., SO₂NH and derivs., alk(en)ylene; R₁, R₂ = independently H, alkyl, CN, halo, etc.; their free bases, acid addition salts, hydrates and solvates] were prepared as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors for treating MGL- and FAAH-related pathologies. Thus, amidation of 4-(3-trifluoromethylphenyl)-1-piperazinecarbonyl chloride with 2-amino-6-chloro-3-nitropyridine, coupling of the chloride with 4-chlorophenylboronic acid, reduction of the nitro intermediate and diazotization/cyclization of the amine gave triazolopyridine carboxamide II. In a radioenzymic test measuring the in vitro inhibitory activity of I towards MGL, II inhibited MGL with IC₅₀ = 0.002 μM. In a radioenzymic test measuring the in vitro inhibitory activity of I towards FAAH, II inhibited FAAH with IC₅₀ = 0.002 μM. I are useful for treating and preventing pathologies in which endogenous 2-arachidonoylglycerol and 1(3)-arachidonoylglycerol and/or other substrate metabolized by MLG and/or in which endogenous anandamide and/or other substrate metabolized by FAAH are implied.


IT 1072874-85-1P, [5-(Furan-3-yl)-[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of triazolopyridine carboxamides as selective monoacyl glycerol lipase or mixed monoacyl glycerol lipase and fatty acid amide hydrolase inhibitors)

RN 1072874-85-1 CAPLUS

CN Methanone, [5-(3-furanyl)-3H-1,2,3-triazolo[4,5-b]pyridin-3-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:26083 CAPLUS

DOCUMENT NUMBER: 148:205319

TITLE: Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38 α MAP kinase inhibitors with excellent in vivo antiinflammatory properties

AUTHOR(S): Mader, Mary; de Dios, Alfonso; Shih, Chuan; Bonjouklian, Rosanne; Li, Tiechao; White, Wesley; Lopez de Uralde, Beatriz; Sanchez-Martinez, Concepcion; del Prado, Miriam; Jaramillo, Carlos; de Diego, Eugenio; Martin Cabrejas, Luisa M.; Dominguez, Carmen; Montero, Carlos; Shepherd, Timothy; Dally, Robert; Toth, John E.; Chatterjee, Arindam; Pleite, Sehila; Blanco-Urgoiti, Jaime; Perez, Leticia; Barberis, Mario; Lorite, Maria Jose; Jambrina, Enrique; Nevill, C. Richard; Lee, Paul A.; Schultz, Richard C.; Wolos, Jeffrey A.; Li, Li C.; Campbell, Robert M.; Anderson, Bryan D.

CORPORATE SOURCE: Centro de Investigacion, Lilly S.A., Eli Lilly and Co., Madrid, 28108, Spain

SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(1), 179-183

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:205319

AB Herein we report investigations into the p38 α MAP kinase activity of trisubstituted imidazoles that led to the identification of compds. possessing highly potent in vivo activity. The SAR of a novel series of imidazopyridines is demonstrated as well, resulting in compds. possessing cellular potency and enhanced in vivo activity in the rat collagen-induced arthritis model of chronic inflammation.


IT 862504-79-8P 862504-97-0P 862505-00-8P
862505-05-3P 862505-19-9P 862505-22-4P
862505-50-8P 862505-55-3P 862505-60-0P
862505-94-0P 862505-99-5P 862506-00-1P
862506-16-9P 862507-23-1P 1005349-47-2P
1005349-48-3P 1005349-49-4P 1005349-52-9P
1005349-53-0P 1005349-54-1P 1005349-55-2P
1005349-56-3P 1005349-57-4P 1005349-58-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(imidazolyl benzimidazoles and imidazopyridines as p38 α MAP kinase inhibitors with antiinflammatory properties)

RN 862504-79-8 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 862504-97-0 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-

fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-00-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-05-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-19-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-22-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-50-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862505-55-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862505-60-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862505-94-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862505-99-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862506-00-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-99-5


CMF C23 H28 N6



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 862506-16-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862507-23-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-00-8


CMF C24 H29 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-47-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862505-50-8


CMF C25 H22 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-48-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862505-94-0


CMF C25 H21 F2 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-49-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862504-79-8


CMF C26 H24 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-52-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862505-55-3


CMF C25 H22 Cl2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-53-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862505-60-0


CMF C25 H20 Cl2 F2 N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 1005349-54-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 862506-16-9
 CMF C23 H26 F2 N6



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 1005349-55-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 862505-22-4
 CMF C26 H24 Cl F N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 1005349-56-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 862504-97-0
CMF C26 H23 F3 N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 1005349-57-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 862505-19-9
CMF C26 H23 Cl2 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-58-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862505-05-3


CMF C24 H28 F2 N6




CM 2

CRN 75-75-2


CMF C H4 O3 S



IT 1005349-46-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (imidazolyl benzimidazoles and imidazopyridines as p38 α MAP
 kinase inhibitors with antiinflammatory properties)
 RN 1005349-46-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-
 imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:1) (CA
 INDEX NAME)
 CM 1
 CRN 862506-70-5
 CMF C24 H20 F2 N6 O2 S



CM 2
 CRN 75-75-2
 CMF C H4 O3 S



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:823708 CAPLUS

DOCUMENT NUMBER: 143:229855

TITLE: Preparation of imidazo-pyridine derivatives as p38 kinase inhibitors

INVENTOR(S): Bonjouklian, Rosanne; Hamdouchi, Chafiq Hamdouchi; Shih, Chuan; De Dios, Alfonso; Del Prado, Miriam Filadelfa; Jaramillo Aguado, Carlos; Kotiyan, Pramila; Mader, Mary Margaret; Selgas, Sheila Pleite; Sanchez-Martinez, Concepcion

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|--|------------|
| ----- | --- | ----- | ----- | ----- |
| WO 2005075478 | A1 | 20050818 | WO 2005-US25 | 20050125 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2005210459 | A1 | 20050818 | AU 2005-210459 | 20050125 |
| CA 2559128 | A1 | 20050818 | CA 2005-2559128 | 20050125 |
| EP 1713805 | A1 | 20061025 | EP 2005-704878 | 20050125 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| CN 1938302 | A | 20070328 | CN 2005-80010142 | 20050125 |
| RU 2348635 | C2 | 20090310 | RU 2006-138606 | 20050125 |
| US 20090036445 | A1 | 20090205 | US 2006-597283 | 20060719 |
| IN 2006MN01085 | A | 20070420 | IN 2006-MN1085 | 20060911 |
| PRIORITY APPLN. INFO.: | | | US 2004-540830P | P 20040130 |
| | | | WO 2005-US25 | W 20050125 |
| OTHER SOURCE(S): | | | CASREACT 143:229855; MARPAT 143:229855 | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = N or CR1; R = alkyl, cycloalkyl, alkylene, etc.; R1 = H, amino, Me, etc.; W = (un)substituted imidazole, pyrazole, oxazole, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of p38 kinase. Thus, e.g., II was prepared by substitutions of 2,6-dichloro-3-nitropyridine with neopentylamine and phenylacetylene followed by oxidation and cyclization with trimethylacetaldehyde to give III. III was then reduced and subsequently treated with cyanogen bromide to yield free base II, which was then converted into the methanesulfonate salt using methanesulfonic acid. The inhibitory activity of I towards p38 kinase was evaluated in scintillation assays and it was revealed that selected compds. of the invention


displayed IC50 values in the range of 2.3 up to 7.2 nM. I as inhibitor of p38 kinase should prove useful in the treatment of multiple myeloma. Pharmaceutical compns. comprising I are disclosed.

IT 862504-88-9P 862505-00-8P 862505-05-3P
862505-07-5P 862505-10-0P 862505-19-9P
862505-22-4P 862505-72-4P 862505-90-6P
862505-97-3P 862506-30-7P 862506-50-1P
862506-60-3P 862506-70-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazo-pyridine derivs. as inhibitors of p38 kinase)


RN 862504-88-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-[4-(4-fluorophenyl)-2-[2-fluoro-6-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-
(CA INDEX NAME)




RN 862505-00-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 862505-05-3 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 862505-07-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862505-10-0 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862505-19-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-22-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-72-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl- (CA INDEX NAME)




RN 862505-90-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-97-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-pyrazol-4-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862506-30-7 CAPLUS

CN Methanimidamide, N'-[5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-3H-imidazo[4,5-b]pyridin-2-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 862506-50-1 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862506-60-3 CAPLUS


CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide, 2-amino-5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 862506-70-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-

imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



IT 862504-77-6P 862504-80-1P 862504-83-4P
 862504-86-7P 862504-89-0P 862504-92-5P
 862504-95-8P 862504-98-1P 862505-01-9P
 862505-03-1P 862505-06-4P 862505-08-6P
 862505-11-1P 862505-14-4P 862505-16-6P
 862505-18-8P 862505-20-2P 862505-23-5P
 862505-26-8P 862505-28-0P 862505-30-4P
 862505-32-6P 862505-35-9P 862505-37-1P
 862505-39-3P 862505-41-7P 862505-44-0P
 862505-47-3P 862505-49-5P 862505-51-9P
 862505-54-2P 862505-56-4P 862505-59-7P
 862505-61-1P 862505-63-3P 862505-67-7P
 862505-70-2P 862505-73-5P 862505-76-8P
 862505-79-1P 862505-82-6P 862505-84-8P
 862505-87-1P 862505-89-3P 862505-91-7P
 862505-93-9P 862505-95-1P 862505-98-4P
 862506-00-1P 862506-03-4P 862506-05-6P
 862506-07-8P 862506-09-0P 862506-12-5P
 862506-15-8P 862506-17-0P 862506-19-2P
 862506-21-6P 862506-23-8P 862506-26-1P
 862506-28-3P 862506-31-8P 862506-33-0P
 862506-35-2P 862506-37-4P 862506-40-9P
 862506-43-2P 862506-46-5P 862506-49-8P
 862506-51-2P 862506-54-5P 862506-56-7P
 862506-59-0P 862506-61-4P 862506-64-7P
 862506-66-9P 862506-68-1P 862506-71-6P
 862506-73-8P 862506-76-1P 862506-79-4P
 862506-81-8P 862506-84-1P 862506-85-2P
 862506-88-5P 862506-91-0P 862506-94-3P
 862506-97-6P 862506-99-8P 862507-01-5P
 862507-04-8P 862507-07-1P 862507-10-6P
 862507-13-9P 862507-15-1P 862507-18-4P
 862507-22-0P 862507-23-1P 862507-25-3P
 862507-27-5P 862507-29-7P 862535-99-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of imidazo-pyridine derivs. as inhibitors of p38 kinase)


RN 862504-77-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-
 imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX
 NAME)

CM 1

CRN 862504-76-5


CMF C24 H30 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862504-80-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862504-79-8


CMF C26 H24 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862504-83-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862504-82-3


CMF C23 H26 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862504-86-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-(2-cyclopropyl-4-phenyl-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862504-85-6


CMF C23 H26 N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862504-89-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-[4-(4-fluorophenyl)-2-[2-fluoro-6-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862504-88-9
 CMF C27 H23 F5 N6



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862504-92-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862504-91-4
 CMF C27 H24 F4 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862504-95-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-cyclopropyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862504-94-7


CMF C23 H25 F N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862504-98-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862504-97-0
 CMF C26 H23 F3 N6



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862505-01-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-00-8
 CMF C24 H29 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-03-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-02-0


CMF C23 H25 F N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862505-06-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862505-05-3
 CMF C24 H28 F2 N6



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 862505-08-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-07-5
 CMF C25 H31 F N6


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 862505-11-1 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-10-0

CMF C27 H25 F3 N6


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-14-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(4-fluorophenyl)-2-[2-fluoro-6-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-13-3
 CMF C28 H25 F5 N6

Absolute stereochemistry.



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862505-16-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-15-5
 CMF C25 H19 Cl2 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-18-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-17-7


CMF C25 H19 F3 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-20-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-19-9


CMF C26 H23 Cl2 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-23-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-22-4


CMF C26 H24 Cl F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-26-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-25-7


CMF C25 H20 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-28-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-27-9


CMF C25 H20 Cl2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-30-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(2,6-difluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-29-1

CMF C26 H22 F4 N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 862505-32-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862505-31-5
CMF C20 H21 F N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 862505-35-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[5-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-34-8
CMF C20 H21 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-37-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-36-0


CMF C25 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-39-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-38-2


CMF C19 H19 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-41-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[1-(1-methylethyl)-3-phenyl-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-40-6


CMF C22 H26 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-44-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-(1-methyl-3-phenyl-1H-pyrazol-4-yl)-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-43-9


CMF C20 H22 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-47-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-methylpropyl)-5-(3-phenyl-1H-pyrazol-4-yl)-, methanesulfonate (1:2) (CA INDEX NAME)


CM 1

CRN 862505-46-2
CMF C19 H20 N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 862505-49-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)


CM 1

CRN 862505-48-4
CMF C19 H18 F2 N6




CM 2


CRN 75-75-2
CMF C H4 O3 S




RN 862505-51-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)
 CM 1
 CRN 862505-50-8
 CMF C25 H22 F2 N6



CM 2
 CRN 75-75-2
 CMF C H4 O3 S




RN 862505-54-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)
 CM 1
 CRN 862505-53-1
 CMF C26 H24 Cl2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-56-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-55-3


CMF C25 H22 C12 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-59-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-58-6


CMF C25 H21 C12 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-61-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-60-0


CMF C25 H20 Cl2 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-63-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-62-2
 CMF C27 H25 Cl F2 N6

Absolute stereochemistry.



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862505-67-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-66-6
 CMF C25 H31 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-70-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-69-9


CMF C27 H25 Cl F N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-73-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-72-4


CMF C27 H25 F2 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-76-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?)
(CA INDEX NAME)

CM 1

CRN 862505-75-7


CMF C27 H24 F3 N5



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862505-79-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862505-78-0
 CMF C27 H24 Cl2 F N5



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862505-82-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(cyclopropylmethyl)-5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-81-5
 CMF C26 H21 F2 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-84-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 3-(cyclopropylmethyl)-5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-83-7


CMF C26 H21 Cl2 N5




CM 2

CRN 75-75-2


CMF C H4 O3 S




RN 862505-87-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 5-(2-cyclopropyl-4-phenyl-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)
 CM 1
 CRN 862505-86-0
 CMF C24 H27 N5




CM 2
 CRN 75-75-2
 CMF C H4 O3 S



RN 862505-89-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)
 CM 1
 CRN 862505-88-2
 CMF C27 H25 Cl2 N5




CRN 75-75-2
CMF C H4 O3 S



RN 862505-91-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862505-90-6
CMF C26 H23 C1 F N5



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 862505-93-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-(2-cyclopropyl-4-phenyl-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-92-8
CMF C23 H25 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-95-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-94-0


CMF C25 H21 F2 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-98-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)


CM 1

CRN 862505-97-3
CMF C22 H25 F N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 862506-00-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)


CM 1

CRN 862505-99-5
CMF C23 H28 N6



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 862506-03-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-02-3


CMF C25 H22 Cl F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-05-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-(2-cyclopropyl-4-phenyl-1H-imidazol-5-yl)-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-04-5

CMF C22 H24 N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 862506-07-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-06-7
CMF C26 H22 F4 N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 862506-09-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-08-9
CMF C25 H21 Cl F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-12-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1-methylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862506-11-4


CMF C22 H26 N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-15-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-[2-fluoro-6-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-14-7
 CMF C26 H20 F6 N6



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862506-17-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-16-9
 CMF C23 H26 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-19-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1-methylethyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?)
(CA INDEX NAME)

CM 1

CRN 862506-18-1


CMF C22 H24 F2 N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-21-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-20-5
 CMF C25 H20 Cl F3 N6



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862506-23-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-cyclopropyl-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-22-7
 CMF C22 H22 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-26-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-cyclopropyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862506-25-0


CMF C22 H23 F N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-28-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)


CM 1

CRN 862506-27-2
 CMF C23 H27 F N6




CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 862506-31-8 CAPLUS
 CN Methanimidamide, N'-[5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-3H-imidazo[4,5-b]pyridin-2-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 862506-33-0 CAPLUS

CN Methanimidamide, N'-[5-[2-(2,6-dichlorophenyl)-1-methyl-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-3H-imidazo[4,5-b]pyridin-2-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 862506-35-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-1-methyl-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862506-37-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-1-methyl-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862506-40-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-(4-phenyl-1H-1,2,3-triazol-5-yl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-39-6


CMF C19 H21 N7



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-43-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-[4-(4-fluorophenyl)-1H-1,2,3-triazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-42-1


CMF C19 H20 F N7



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-46-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[4-(4-fluorophenyl)-1H-1,2,3-triazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-45-4


CMF C18 H16 F N7



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-49-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-(4-phenyl-1H-1,2,3-triazol-5-yl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-48-7


CMF C18 H17 N7



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-51-2 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-50-1
 CMF C24 H20 Cl F N6



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862506-54-5 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-53-4
 CMF C24 H20 Cl2 N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 862506-56-7 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(2,6-dichlorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-55-6
CMF C24 H18 Cl2 F2 N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 862506-59-0 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-58-9
CMF C22 H25 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-61-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,
2-amino-5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-N,N-dimethyl-,
methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-60-3


CMF C21 H25 N7 O2 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-64-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,
 2-amino-5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-N,N-
 dimethyl-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-63-6
 CMF C23 H19 Cl F N7 O2 S



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862506-66-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,
 2-amino-5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-N,N-dimethyl-
 , methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-65-8
 CMF C23 H19 Cl2 N7 O2 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-68-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,
2-amino-5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-
N,N-dimethyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-67-0


CMF C21 H23 F2 N7 O2 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-71-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-70-5
 CMF C24 H20 F2 N6 O2 S



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862506-73-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-72-7
 CMF C25 H22 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-76-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-(2-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862506-75-0


CMF C25 H23 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-79-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-78-3


CMF C25 H22 Cl F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-81-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-80-7


CMF C23 H28 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-84-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-83-0


CMF C26 H22 F4 N6



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 862506-85-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,
2-amino-N,N-dimethyl-5-(5-phenyl-2H-1,2,3-triazol-4-yl)- (CA INDEX NAME)




RN 862506-88-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-87-4


CMF C25 H20 F4 N6 O2 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-91-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-90-9


CMF C22 H26 N6 O2 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-94-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-93-2
 CMF C24 H20 Cl2 N6 O2 S



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862506-97-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-96-5
 CMF C24 H20 Cl F N6 O2 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-99-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-98-7


CMF C23 H26 F2 N6



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 862507-01-5 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-5-oxazolyl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862507-04-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-5-oxazolyl]-3-(2-methylpropyl)-, methanesulfonate (1:?)
 (CA INDEX NAME)


CM 1

CRN 862507-03-7
 CMF C23 H25 F2 N5 O



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 862507-07-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-oxazolyl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862507-06-0
 CMF C22 H24 F N5 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862507-10-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-(2-methyl-4-phenyl-5-thiazolyl)-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862507-09-3


CMF C20 H21 N5 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862507-13-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(4-fluorophenyl)-2-methyl-5-thiazolyl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862507-12-8
 CMF C20 H20 F N5 S




CM 2

CRN 75-75-2
 CMF C H4 O3 S



RN 862507-15-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide, 2-amino-5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-5-oxazolyl]-N,N-dimethyl- (CA INDEX NAME)




RN 862507-18-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,
2-amino-5-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-oxazolyl]-N,N-dimethyl-,
methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862507-17-3


CMF C20 H21 F N6 O3 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862507-22-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-,
(2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 862505-00-8

CMF C24 H29 F N6




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 862507-23-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-00-8


CMF C24 H29 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862507-25-3 CAPLUS

CN Butanedioic acid, compd. with 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 862505-00-8


CMF C24 H29 F N6



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 862507-27-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 862505-00-8

CMF C24 H29 F N6




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 862507-29-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 862535-99-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862535-98-6


CMF C25 H30 F N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




IT 862505-50-8 862505-55-3 862507-99-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of imidazo-pyridine derivs. as inhibitors of p38 kinase)


RN 862505-50-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862505-55-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862507-99-1 CAPLUS

CN Methanimidamide, N'-[5-[2-(2,6-difluorophenyl)-1-methyl-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-3H-imidazo[4,5-b]pyridin-2-yl]-N,N-dimethyl- (CA INDEX NAME)



IT 862535-98-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of imidazo-pyridine derivs. as inhibitors of p38 kinase)
 RN 862535-98-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

24.06

399.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.28

-3.28

STN INTERNATIONAL LOGOFF AT 14:26:00 ON 17 APR 2009